Actuate Therapeutics, Inc. Common stock (ACTU) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Actuate Therapeutics, Inc. Common stock stock (ACTU) is currently trading at $2.21. Analyst consensus price target for ACTU is $26.75. WallStSmart rates ACTU as Sell.
- ACTU PE ratio analysis and historical PE chart
- ACTU PS ratio (Price-to-Sales) history and trend
- ACTU intrinsic value — DCF, Graham Number, EPV models
- ACTU stock price prediction 2025 2026 2027 2028 2029 2030
- ACTU fair value vs current price
- ACTU insider transactions and insider buying
- Is ACTU undervalued or overvalued?
- Actuate Therapeutics, Inc. Common stock financial analysis — revenue, earnings, cash flow
- ACTU Piotroski F-Score and Altman Z-Score
- ACTU analyst price target and Smart Rating
Actuate Therapeutics, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Actuate Therapeutics, Inc. Common stock (ACTU) · 3 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap. Significant fundamental concerns warrant caution or avoidance.
Actuate Therapeutics, Inc. Common stock (ACTU) Key Strengths (0)
Supporting Valuation Data
Actuate Therapeutics, Inc. Common stock (ACTU) Areas to Watch (3)
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 5.0x book value
Moderate institutional interest at 49.73%
Actuate Therapeutics, Inc. Common stock (ACTU) Detailed Analysis Report
Overall Assessment
This company scores 12/100 in our Smart Analysis, earning a F grade. Out of 3 metrics analyzed, 0 register as strengths (avg 0/10) while 3 fall into concern territory (avg 4.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Market Cap, Price/Book, Institutional Own.. Some valuation metrics including Price/Book (5.00) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Market Cap improves, as this is the primary drag on the overall score. Second, overall profitability trends. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Market Cap and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ACTU Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:21:56 AM
About Actuate Therapeutics, Inc. Common stock(ACTU)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients facing serious diseases, with a particular focus on oncology. The company is advancing its proprietary drug candidates through rigorous clinical trials aimed at addressing significant unmet medical needs and enhancing patient outcomes. By concentrating on novel therapeutic mechanisms, Actuate is building a robust pipeline with the potential for strategic growth and investor value creation, positioning itself as a key player in the biotechnology landscape as it strives to make a meaningful impact.